Lido Advisors LLC Makes New Investment in Tarsus Pharmaceuticals, Inc. $TARS

Lido Advisors LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 24,374 shares of the company’s stock, valued at approximately $1,710,000. Lido Advisors LLC owned approximately 0.06% of Tarsus Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Tarsus Pharmaceuticals by 5.6% during the fourth quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock worth $196,476,000 after acquiring an additional 127,470 shares during the last quarter. TimesSquare Capital Management LLC raised its position in shares of Tarsus Pharmaceuticals by 24.3% in the 4th quarter. TimesSquare Capital Management LLC now owns 332,446 shares of the company’s stock valued at $27,221,000 after purchasing an additional 64,941 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Tarsus Pharmaceuticals by 19.9% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 109,857 shares of the company’s stock worth $8,995,000 after purchasing an additional 18,267 shares in the last quarter. D.A. Davidson & CO. acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter worth approximately $1,493,000. Finally, Ishara Investments LP purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter worth approximately $1,965,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, Director Katherine Goodrich sold 2,954 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $62.08, for a total value of $183,384.32. Following the completion of the transaction, the director owned 2,233 shares of the company’s stock, valued at $138,624.64. The trade was a 56.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak R. Azamian sold 10,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $61.55, for a total value of $615,500.00. Following the completion of the transaction, the chief executive officer directly owned 847,991 shares of the company’s stock, valued at approximately $52,193,846.05. This trade represents a 1.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 39,850 shares of company stock valued at $2,452,821 in the last three months. Company insiders own 9.64% of the company’s stock.

Wall Street Analysts Forecast Growth

TARS has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $88.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Oppenheimer began coverage on Tarsus Pharmaceuticals in a research report on Friday, April 24th. They issued an “outperform” rating and a $98.00 target price on the stock. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Guggenheim lowered their price target on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Tuesday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.50.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS opened at $58.66 on Monday. The company has a 50 day simple moving average of $61.54 and a two-hundred day simple moving average of $65.92. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -51.46 and a beta of 0.50. The company has a current ratio of 3.74, a quick ratio of 3.71 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. The firm had revenue of $162.05 million for the quarter, compared to analyst estimates of $149.60 million. As a group, analysts predict that Tarsus Pharmaceuticals, Inc. will post -1.04 earnings per share for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.